Get the Stockscreener App
2.35
3.29%
-0.08
Clearmind Medicine Inc stock is traded at $2.35, with a volume of 40,747.
It is down -3.29% in the last 24 hours and down -51.73% over the past month.
Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
See More
Previous Close:
$2.43
Open:
$2.46
24h Volume:
40,747
Relative Volume:
0.12
Market Cap:
$3.52M
Revenue:
-
Net Income/Loss:
$-6.78M
P/E Ratio:
-0.055
EPS:
-42.6996
Net Cash Flow:
$-4.67M
1W Performance:
+18.09%
1M Performance:
-51.73%
6M Performance:
-93.94%
1Y Performance:
-95.92%
1-Day Range:
$2.31
$2.4981
1-Week Range:
$2.055
$2.74
52-Week Range:
$1.743
$64.80
Clearmind Medicine Inc Stock (CMND) Company Profile
Compare CMND with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMND
Clearmind Medicine Inc
|
2.35 | 3.64M | 0 | -6.78M | -4.67M | -42.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Clearmind Medicine Inc Stock (CMND) Latest News
Why Clearmind Medicine Inc. stock remains on buy listsTrail vs Road Selection & compare fit, width, and feel - ulpravda.ru
Will Clearmind Medicine Inc. stock deliver shareholder value2025 Breakouts & Breakdowns & Weekly Top Gainers Alerts - ulpravda.ru
Published on: 2026-01-09 01:57:04 - ulpravda.ru
Does Clearmind Medicine Inc. (CWY0) stock trade below intrinsic valueQuarterly Investment Review & Scalable Portfolio Growth Methods - ulpravda.ru
Will Clearmind Medicine Inc. stock benefit from AI adoptionStock Buy Signals & Target Triple-Digit Stock Opportunities - ulpravda.ru
Surprises Report: Why Clearmind Medicine Inc stock is recommended by analystsChart Signals & Safe Swing Trade Setups - moha.gov.vn
How geopolitical tensions affect Clearmind Medicine Inc. stock2026 world cup usa national team group stage defensive leaders possession football match prediction insights - ulpravda.ru
Why retail traders accumulate Clearmind Medicine Inc. (CWY0) stockStop Loss Placement Tips & Build Wealth With Zero-Cost Tools - bollywoodhelpline.com
Portfolio Shifts: Why Clearmind Medicine Inc stock is recommended by analystsRate Cut & Reliable Price Action Trade Plans - moha.gov.vn
Clearmind Medicine (CMND) Stock Analysis Report | Financials & Insights - Benzinga España
Clearmind Medicine Announces the Notice of an International Patent App... - Moscow-Pullman Daily News
Clearmind Medicine regains compliance with NASDAQ minimum bid price rule - MSN
Clearmind regains Nasdaq compliance as shares maintain $1 minimum - Investing.com India
Clearmind Medicine Says Nasdaq Compliance Regained on Minimum Bid Price Rule - MarketScreener
Clearmind regains Nasdaq compliance as shares maintain $1 minimum By Investing.com - Investing.com Canada
Clearmind Medicine regains compliance with Nasdaq minimum bid price rule - TipRanks
Clearmind Medicine Inc. Regains Compliance with Nasdaq Listing Requirements - Quiver Quantitative
Clearmind Medicine Regains Compliance with Nasdaq Minimum Bid Price Requirement - marketscreener.com
Clearmind Medicine highlights key 2025 achievements - MSN
Clearmind advances AUD treatment as phase I/IIa trial progresses By Investing.com - Investing.com Australia
Clearmind advances AUD treatment as phase I/IIa trial progresses - Investing.com
Clearmind Medicine Inc. Reflects on Major Progress in 2025 Clinical Trials for CMND-100 Targeting Alcohol Use Disorder - Quiver Quantitative
Clearmind Medicine Reflects on a Transformative 2025: Key Clinical Advancements, Expanded Global Reach, and Strengthened Foundation for Future Growth - Yahoo Finance
Psychedelic: Clearmind completes second cohort enrollment for CMND-100 trial - MSN
Cash from operating activities of Clearmind Medicine Inc. – MUN:CWY - TradingView — Track All Markets
Trading Recap: How strong is Clearmind Medicine Inc. stock balance sheetJuly 2025 Selloffs & Weekly Setup with ROI Potential - moha.gov.vn
How interest rate cuts could boost Clearmind Medicine Inc. stock2025 Geopolitical Influence & Short-Term High Return Ideas - Улправда
Clearmind Medicine Inc. (NASDAQ: CMND)Share Price - intelligentinvestor.com.au
Published on: 2025-12-19 05:54:25 - Улправда
Pretax income of Clearmind Medicine Inc. – LS:A41YK5 - TradingView — Track All Markets
Clearmind Medicine completes second cohort enrollment in Phase I/IIa AUD trial - MSN
Free float of Clearmind Medicine Inc. – LSX:A41YK5 - TradingView — Track All Markets
Cash from financing activities of Clearmind Medicine Inc. – FWB:CWY - TradingView — Track All Markets
Cost of goods sold of Clearmind Medicine Inc. – LSX:A41YK5 - TradingView — Track All Markets
Gross profit of Clearmind Medicine Inc. – LSX:A41YK5 - TradingView — Track All Markets
EBIT of Clearmind Medicine Inc. – LSX:A41YK5 - TradingView — Track All Markets
EBIT per share of Clearmind Medicine Inc. – LSX:A41YK5 - TradingView — Track All Markets
Diluted earnings per share (diluted EPS) of Clearmind Medicine Inc. – LSX:A41YK5 - TradingView — Track All Markets
Long term debt to total assets ratio of Clearmind Medicine Inc. – LSX:A41YK5 - TradingView — Track All Markets
Basic earnings per share (basic EPS) of Clearmind Medicine Inc. – LSX:A41YK5 - TradingView — Track All Markets
Non-operating income (total) of Clearmind Medicine Inc. – LSX:A41YK5 - TradingView — Track All Markets
Operating expenses (excl. COGS) of Clearmind Medicine Inc. – LSX:A41YK5 - TradingView — Track All Markets
Clearmind Medicine Inc. Balance Sheet – LSX:A41YK5 - TradingView — Track All Markets
Price to cash flow ratio of Clearmind Medicine Inc. – LSX:A41YK5 - TradingView — Track All Markets
Diluted net income available to common stockholders of Clearmind Medicine Inc. – LSX:A41YK5 - TradingView — Track All Markets
Operating cash flow per share of Clearmind Medicine Inc. – LSX:A41YK5 - TradingView — Track All Markets
CapEx per share of Clearmind Medicine Inc. – LSX:A41YK5 - TradingView — Track All Markets
Enterprise value to EBITDA ratio of Clearmind Medicine Inc. – LSX:A41YK5 - TradingView — Track All Markets
Operating margin % of Clearmind Medicine Inc. – LSX:A41YK5 - TradingView — Track All Markets
Total revenue of Clearmind Medicine Inc. – LSX:A41YK5 - TradingView — Track All Markets
Published on: 2025-12-18 16:01:28 - Улправда
Clearmind Medicine Inc Stock (CMND) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):